Literature DB >> 32433947

The CD47-SIRPα Immune Checkpoint.

Meike E W Logtenberg1, Ferenc A Scheeren2, Ton N Schumacher3.   

Abstract

The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein, expressed on both healthy and cancer cells, plays a pivotal role in this balance by delivering a "don't eat me signal" upon binding to the Signal-regulatory protein alpha (SIRPα) receptor on myeloid cells. Here, we review the current understanding of the role of the CD47-SIRPα axis in physiological tissue homeostasis and as a promising therapeutic target in, among others, oncology, fibrotic diseases, atherosclerosis, and stem cell therapies. We discuss gaps in understanding and highlight where additional insight will be beneficial to allow optimal exploitation of this myeloid cell checkpoint as a target in human disease.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32433947      PMCID: PMC7340539          DOI: 10.1016/j.immuni.2020.04.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  95 in total

1.  Refining structural and functional predictions for secretasome components by comparative sequence analysis.

Authors:  Arcady Mushegian
Journal:  Proteins       Date:  2002-04-01

2.  Localized CD47 blockade enhances immunotherapy for murine melanoma.

Authors:  Jessica R Ingram; Olga S Blomberg; Jonathan T Sockolosky; Lestat Ali; Florian I Schmidt; Novalia Pishesha; Camilo Espinosa; Stephanie K Dougan; K Christopher Garcia; Hidde L Ploegh; Michael Dougan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

3.  MYC regulates the antitumor immune response through CD47 and PD-L1.

Authors:  Stephanie C Casey; Ling Tong; Yulin Li; Rachel Do; Susanne Walz; Kelly N Fitzgerald; Arvin M Gouw; Virginie Baylot; Ines Gütgemann; Martin Eilers; Dean W Felsher
Journal:  Science       Date:  2016-03-10       Impact factor: 47.728

4.  Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Authors:  Kipp Weiskopf; Aaron M Ring; Chia Chi M Ho; Jens-Peter Volkmer; Aron M Levin; Anne Kathrin Volkmer; Engin Ozkan; Nathaniel B Fernhoff; Matt van de Rijn; Irving L Weissman; K Christopher Garcia
Journal:  Science       Date:  2013-05-30       Impact factor: 47.728

5.  Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Authors:  Vanessa Buatois; Zoë Johnson; Susana Salgado-Pires; Anne Papaioannou; Eric Hatterer; Xavier Chauchet; Françoise Richard; Leticia Barba; Bruno Daubeuf; Laura Cons; Lucile Broyer; Matilde D'Asaro; Thomas Matthes; Simon LeGallou; Thierry Fest; Karin Tarte; Robert K Clarke Hinojosa; Eulàlia Genescà Ferrer; José María Ribera; Aditi Dey; Katharine Bailey; Adele K Fielding; Linda Eissenberg; Julie Ritchey; Michael Rettig; John F DiPersio; Marie H Kosco-Vilbois; Krzysztof Masternak; Nicolas Fischer; Limin Shang; Walter G Ferlin
Journal:  Mol Cancer Ther       Date:  2018-05-09       Impact factor: 6.261

6.  CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.

Authors:  P A Oldenborg; H D Gresham; F P Lindberg
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

7.  Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells.

Authors:  Richard K Tsai; Dennis E Discher
Journal:  J Cell Biol       Date:  2008-03-10       Impact factor: 10.539

8.  CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.

Authors:  Yoko Kojima; Jens-Peter Volkmer; Kelly McKenna; Mete Civelek; Aldons Jake Lusis; Clint L Miller; Daniel Direnzo; Vivek Nanda; Jianqin Ye; Andrew J Connolly; Eric E Schadt; Thomas Quertermous; Paola Betancur; Lars Maegdefessel; Ljubica Perisic Matic; Ulf Hedin; Irving L Weissman; Nicholas J Leeper
Journal:  Nature       Date:  2016-07-20       Impact factor: 49.962

9.  Synapse maturation by activity-dependent ectodomain shedding of SIRPα.

Authors:  Anna B Toth; Akiko Terauchi; Lily Y Zhang; Erin M Johnson-Venkatesh; David J Larsen; Michael A Sutton; Hisashi Umemori
Journal:  Nat Neurosci       Date:  2013-09-15       Impact factor: 24.884

10.  miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47.

Authors:  Seung Yeob Yang; Seung Ah Choi; Ji Yeoun Lee; Ae-Kyung Park; Kyu-Chang Wang; Ji Hoon Phi; Eun Jung Koh; Woong-Yang Park; Sung-Hye Park; Do Won Hwang; Hee Won Jung; Seung-Ki Kim
Journal:  Oncotarget       Date:  2015-12-22
View more
  70 in total

Review 1.  Novel immunotherapies in multiple myeloma.

Authors:  Ken Ohmine; Ryosuke Uchibori
Journal:  Int J Hematol       Date:  2022-05-18       Impact factor: 2.490

Review 2.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

3.  Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Kyle V Cicalese; Rajdeep Bannerjee; David D Roberts
Journal:  Antib Ther       Date:  2020-08-08

4.  Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.

Authors:  Felicia Cao; Phuong Nguyen; Bangxing Hong; Christopher DeRenzo; Nino C Rainusso; Tania Rodriguez Cruz; Meng-Fen Wu; Hao Liu; Xiao-Tong Song; Masataka Suzuki; Lisa L Wang; Jason T Yustein; Stephen Gottschalk
Journal:  Adv Cell Gene Ther       Date:  2020-07-03

Review 5.  Neutrophil dynamics in the tumor microenvironment.

Authors:  Amanda J McFarlane; Frédéric Fercoq; Seth B Coffelt; Leo M Carlin
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

6.  Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.

Authors:  Xuefei Zhou; Xiangrui Liu; Leaf Huang
Journal:  Adv Funct Mater       Date:  2020-11-10       Impact factor: 18.808

7.  Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Authors:  Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen
Journal:  Biomolecules       Date:  2021-05-10

Review 8.  Immunotherapy in the treatment of lymphoma.

Authors:  Lazar S Popovic; Gorana Matovina-Brko; Maja Popovic; Milica Popovic; Ana Cvetanovic; Ivan Nikolic; Biljana Kukic; Dragana Petrovic
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

9.  Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma.

Authors:  Qiangqiang Zhao; Duanfeng Jiang; Xiaoying Sun; Qiuyu Mo; Shaobin Chen; Wansong Chen; Rong Gui; Xianjun Ma
Journal:  J Nanobiotechnology       Date:  2021-06-13       Impact factor: 10.435

Review 10.  CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways.

Authors:  Seyed Mohammad Gheibihayat; Ricardo Cabezas; Nikita G Nikiforov; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.